Skip to content

DMT: all studies

Page 68 of 160: studies 671 to 680 of 1,593, newest first. Back to the DMT overview

Research

Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1

June 21, 2026 Camille Racca, Cécilie Cordier

This protocol describes a systematic review and meta-analysis assessing the efficacy and safety of classic serotonergic psychedelics and related serotonergic ergoline or lysergamide compounds in cluster headache and migraine. The review will include clinical studies evaluating psilocybin, psilocin, LSD, LSA, DMT/ayahuasca, mescaline, BOL-148 / 2-bromo-LSD / bromolysergide, lisuride,...

Ego dissolution as a collapse of integration, not a surge of entropy

Zenodo (CERN European Organization for Nuclear Research) June 18, 2026 Sören van Krunckelsven preprint

AbstractThe “entropic brain” hypothesis holds that psychedelic and other ego-dissolving states correspondto an increase in the entropy or signal diversity of spontaneous brain activity. Motivated by afirst-person report of a combined serotonergic–dissociative state (LSD/DMT together with nitrousoxide, N2O), we asked a sharper question: when a 5-HT2A agonist and an NMDA antagonist acttogether,...

DOI: 10.5281/zenodo.20751383 (opens in new tab) Nmda receptor Control theory sociology Noise video Agonist +2

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.

ACS Chemical Neuroscience June 17, 2026 Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.

Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...

Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research

Biomedicine & Pharmacotherapy June 17, 2026 Małgorzata Potoczna, Natalia Kasica, Małgorzata Chmielewska-Krzesińska et al.

Zebrafish larvae are increasingly used in behavioural pharmacology because of their translational relevance and suitability for anxiety- and stress-related studies. However, it remains unclear whether commonly used behavioural assays and molecular stress markers provide convergent evidence of anxiolytic-like drug activity. This study therefore aimed not to validate a single predictive screening...

DOI: 10.1016/j.biopha.2026.119680 (opens in new tab) Zebrafish Drug discovery Screening techniques Phenotypic screening +4

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.

ACS Pharmacology & Translational Science June 12, 2026 Tianshu Zhang, Cong Lin, Xiaohui Wang

Classic serotonergic psychedelics-such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT)-hold remarkable promise for treating neuropsychiatric disorders, yet their clinical translation is severely constrained by first-pass metabolism, erratic pharmacokinetics, unsuitable action profiles, and off-target peripheral serotonin effects. To overcome these barriers,...

DOI: 10.1021/acsptsci.6c00146 (opens in new tab) Full text (opens in new tab) Drug delivery systems Intranasal administration Microneedle arrays Pharmacokinetics +2

The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.

Acta Neuropsychiatrica June 10, 2026 Helerin Raikkerus, Andrea Bujour, Mark Kennedy et al.

Attention deficit and hyperactivity disorder (ADHD) is a prevalent neuropsychiatric disorder (Drechsler et al., 2020). Recently, psychedelics have become of interest regarding developing treatment options for ADHD. The aim of this systematic review is to find all studies from the APA PsychInfo and MEDLINE databases, where psychedelics have been used for ADHD and assess whether further clinical...

Dynamic Neural State Transitions Predict Psychedelic Phenomenal Richness: Magnitude, Not Direction, Drives Subjective Intensity

Zenodo (CERN European Organization for Nuclear Research) June 9, 2026 Emma Dobbin preprint

UPDATED 2026-06-09 Corrected dataset attribution from Timmermann et al. (2019) to Pallavicini et al. (2021) UPDATED 2026-01-21 Background: Psychedelic substances produce profound alterations in conscious experience, yet the neural mechanisms underlying phenomenal richness remain poorly understood. Static measures of neural integration and complexity have shown limited success in predicting...

DOI: 10.5281/zenodo.18167552 (opens in new tab) Mysticism Consciousness Species richness Neural activity +10

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.

Drugs June 4, 2026 Kevin F. Boehnke, Niloufar Pouyan, Jacob S. Aday

Chronic pain is common, costly, and for many, remains inadequately treated by existing pharmacologic and non-pharmacologic approaches. In parallel with growing dissatisfaction with conventional therapies, classic serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ayahuasca, N,N-dimethyltryptamine (DMT), and mescaline, administered alone or within...

Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.

The Journal of Clinical Psychiatry June 3, 2026 Martin Johnson, Pau Aceves Baldo, Emilio Arbe et al.

Objective: Postpartum depression (PPD) is a debilitating mood disorder with peripartum onset. Current treatment options are limited in PPD. GH001 is a synthetic inhalation formulation of the psychoactive molecule mebufotenin (5-MeO-DMT). This trial investigated the preliminary efficacy and safety of GH001 in adult females with PPD. Methods: This phase 2a, proof-of-concept, open-label trial...

Psychedelic Renaissance: A New Paradigm in Mental Health

European Psychiatry June 1, 2026 A. M. Matas Ochoa, A. R. Quiroga, I. D. Sacristán

Introduction Psychedelics are hallucinogenic agents that are awakening scientific interest in recent years, especially in the field of mental health. Psychedelics induce non-ordinary states of consciousness and alterations in the emotions and in cognition and could be beneficial in treating some mental illness. Objectives The objective of the poster is to expand knowledge about emerging...